Not exact matches
«While the presence of lymphocytes in
tumors is
often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the
tumor environment and their influence on
ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.
Ovarian cancer has one of the highest death rates of all gynecological cancers, because the
tumor often can not be detected until the late stages.
In humans, colon cancer
often spreads to the liver and forms small
tumors that are difficult to detect, similar to
ovarian tumors.
Coukos, who is currently leading an
ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are
often ineffective for these patients, even though
ovarian tumors are
often infiltrated by «killer» T cells that recognize
tumor - specific neoantigens and express high levels of PD - 1.
Spaying females can greatly reduce the possibilities of mammary
tumors later in life (
often malignant) and eliminates the possibilities of pyometra (life threatening infection of the uterus) or
ovarian cancer.
Ovarian cancer sometimes is found during a pelvic exam, but
tumors are
often too deep within the body for doctors to detect.